Losartan Potassium Tablets, 50 Mg Tablet
Product Images NDC 71335-1817

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 50 Mg (NDC 71335-1817). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium, Usp (Structure)

Losartan Potassium, Usp (Structure)
Chemical structure of losartan potassium showing its molecular composition and arrangement of atoms including chlorine, nitrogen, carbon, and potassium ions.*
FDA Label Image

Figure 3 (Figure3)

Figure 3 (Figure3)
A comparative chart titled 'Primary Endpoint Events within Demographic Subgroups' displaying hazard ratios with 95% confidence intervals for Losartan and Atenolol across patient subgroups. Two panels show event rates for Primary Composite and Stroke (Fatal/Non-fatal) outcomes by age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease, with symbols proportional to sample size, illustrating relative favorability between Losartan and Atenolol.*
FDA Label Image

Figure 1 (Figure1)

Figure 1 (Figure1)
A line graph comparing the percentage of patients with a primary endpoint over time between Atenolol and Losartan Potassium. The x-axis represents study months from 0 to 66, and the y-axis shows the percentage of patients from 0 to 16%. The graph includes an annotation indicating an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium.*
FDA Label Image

Figure 2 (Figure2)

Figure 2 (Figure2)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months between two treatments: Atenolol (dotted line) and Losartan Potassium (solid line). The graph shows adjusted risk reduction of 25% with Losartan Potassium (p=0.001) versus Atenolol.*
FDA Label Image

Figure 4.jpg (Figure4)

Figure 4.jpg (Figure4)
A line graph showing the percentage of patients with events over 48 months comparing Losartan Potassium and Placebo. The graph includes a risk reduction value of 16.1% with a p-value of 0.022, illustrating the comparative event rates over time between the two groups.*
FDA Label Image

Label (Lbl713351817)

Label (Lbl713351817)
Label for Losartan Potassium 50 mg Tablets by Bryant Ranch Prepack, packaging 30 tablets. The label states it is comparable to Cozaar 50 mg Tablet by Jubilant Cadista Pharma Inc. Includes storage instructions at 20°-25°C and a warning to keep drugs out of children's reach. Displays NDC 71335-1817 and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.